Holly Smithson Joins Syantra's Board of Directors
Syantra, Inc., a cutting-edge biotechnology firm, is thrilled to announce the recent appointment of Holly Smithson to its Board of Directors. This marks a significant step for the company as it focuses on delivering its innovative cancer detection platform, Onco-ID.
A Leader in STEM and Cancer Advocacy
Holly Smithson is not just a celebrated breast cancer survivor; she is also a passionate advocate for women in STEM. Her experiences as a TEDx speaker emphasize the importance of health empowerment and early cancer detection technologies—an ethos that aligns perfectly with Syantra's mission.
Transformative Journey
Holly's personal battle with breast cancer has shaped her commitment to improving cancer detection methods. Her journey of resilience motivates her to inspire others to reclaim their health and pursue innovation in cancer diagnostics.
CEO of Athena
As the current CEO of Athena, Holly is at the forefront of pushing for gender equality and empowering women within the science and technology sectors. Under her leadership, Athena has sparked a global movement, equipping women leaders and their allies with the tools they need to thrive in competitive industries.
Impressive Career Background
Holly's professional journey is nothing short of remarkable. She has been instrumental in launching and revamping three different companies in the realms of cleantech, biotech, and STEM. Her diverse experience adds immense value to Syantra as it gears up for its next phase of growth.
Government Service
In her earlier career, Holly served as a Presidential Appointee during President George W. Bush's administration, where she played a critical role in advancing significant environmental initiatives at the EPA and State Department. Furthermore, she represented California in a cleantech trade mission to China, successfully building international collaborations in clean technologies.
Recognized Leadership
Holly's accolades are a testament to her influential impact. Inducted into the San Diego Women’s Hall of Fame in 2023, she has frequently been listed among San Diego’s Top 500 Most Influential Leaders and has received honors including CEO of the Year and Businesswoman of the Year, reflecting her contributions to society and industry.
A Personal Mission
Expressing her sentiments on joining Syantra, Holly stated, "I am deeply honored to join Syantra's Board of Directors. As a breast cancer survivor and advocate, I know firsthand the life-saving importance of early detection." She values Syantra's approach to cancer detection and is excited to contribute to the launch of the Onco-ID platform.
CEO's Remarks
Rob Lozuk, Syantra's CEO, praised Holly's unique combination of personal experience and professional expertise, stating, "Her work in STEM, healthcare, and women’s advocacy aligns flawlessly with our mission to enhance patient outcomes through innovative biotechnology." He emphasized that Holly's strong leadership comes at a pivotal moment as they prepare to commercialize Onco-ID, currently undergoing a global clinical study aimed at improving breast cancer detection.
About Syantra
Founded by a dedicated team of innovators based in Calgary, Syantra, Inc. is a precision biotechnology company committed to pioneering transformative cancer detection and treatment technologies. By leveraging the latest advancements in biomedical engineering and medicine, Syantra aims to revolutionize how cancer is diagnosed and treated, ensuring better outcomes for patients worldwide.
Frequently Asked Questions
1. Who is Holly Smithson?
Holly Smithson is a breast cancer survivor, TEDx speaker, and the CEO of Athena, dedicated to empowering women in STEM.
2. What role has she taken on at Syantra?
Holly Smithson has been appointed to Syantra's Board of Directors to aid in the commercialization of its cancer detection platform, Onco-ID.
3. What is the Onco-ID platform?
Onco-ID is Syantra's innovative technology designed for the early detection of cancer by analyzing the body's signals.
4. How does Holly contribute to Syantra's mission?
Her advocacy for early cancer detection and her extensive experience in the biotech field contribute to Syantra's goals of improving patient outcomes.
5. What recognition has Holly received for her work?
Holly has been inducted into the San Diego Women's Hall of Fame and recognized as CEO of the Year and Businesswoman of the Year.
